|
AU2005210687A1
|
|
Crystal structures and models for Fc receptors and uses thereof in the design or identification of Fc receptor modulator compounds
|
|
WO2005075512A1
|
|
Crystal structures and models for fc receptors and uses thereof in the design or identification of fc receptor modulator compounds
|
|
AU2004289707A1
|
|
DNA-carrier conjugate
|
|
US2007258993A1
|
|
Dna-Carrier Conjugate
|
|
ZA200302025B
|
|
Composition comprising immunogenic microparticles.
|
|
WO02081688A1
|
|
Dna molecules encoding igb3 synthase, and uses thereof for the disruption of glycosyltransferase genes in xenotransplantation tissues and organs
|
|
US7318924B2
|
|
Antibodies against cancer
|
|
AU2616502A
|
|
Methods for reducing hyperacute rejection of xenografts
|
|
NZ524843A
|
|
Composition comprising immunogenic microparticles
|
|
AU8737501A
|
|
Composition comprising immunogenic microparticles
|
|
AU6365301A
|
|
Vaccine
|
|
WO0157068A1
|
|
Mucin-1 derived antigens and their use in immunotherapy
|
|
AU2987701A
|
|
Mucin-1 derived antigens and their use in immunotherapy
|
|
AU6970700A
|
|
Method and compositions for the reduction of xenotransplantation rejection
|
|
AUPQ839900A0
|
|
FceReceptor mimicks and antagonists
|
|
US6548643B1
|
|
Antigen carbohydrate compounds and their use in immunotherapy
|
|
AUPQ552800A0
|
|
Promoters and regulators thereof
|
|
AUPQ536900A0
|
|
Antigens and their use in immunotherapy
|
|
AU4017899A
|
|
Methods for reducing hyperacute rejection of xenografts
|
|
WO9916455A1
|
|
Mannose receptor bearing cell line and antigen composition
|
